Publications by authors named "Mathias Baedeker"

Claim this Profile
2
2024 FDA approvals exceed average number but have lower sales projections.
Mathias Baedeker, Michael S Ringel, Clemens C Möller

Nat Rev Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2023 FDA approvals: unprecedented volume at moderate value.
Mathias Baedeker, Michael S Ringel, Clemens C Möller

Nat Rev Drug Discov· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2022 FDA approval number dips: a COVID-19 hangover?
Mathias Baedeker, Michael S Ringel, Clemens C Möller, Ulrik Schulze

Nat Rev Drug Discov· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2021 FDA approvals: value driven by COVID-19 vaccines.
Mathias Baedeker, Michael S Ringel, Ulrik Schulze

Nat Rev Drug Discov· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2020 FDA approvals: momentum kept despite COVID-19, but value falls.
Mathias Baedeker, Michael Ringel, Ulrik Schulze

Nat Rev Drug Discov· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breaking Eroom's Law.
Michael S Ringel, Jack W Scannell, Mathias Baedeker, Ulrik Schulze

Nat Rev Drug Discov· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of 2019 FDA approvals: back to the recent average.
Mathias Baedeker, Michael Ringel, Ulrik Schulze

Nat Rev Drug Discov· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2018 FDA approvals hit all time high - but average value slips again.
Mathias Baedeker, Michael Ringel, Ulrik Schulze

Nat Rev Drug Discov· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market watch: 2017 FDA drug approvals: number rebounds but average value slips.
Mathias Baedeker, Michael Ringel, Valery Panier, Ulrik Schulze

Nat Rev Drug Discov· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market watch: Value of 2016 FDA drug approvals: reversion to the mean?
Ulrik Schulze, Michael Ringel, Valery Panier, Mathias Baedeker

Nat Rev Drug Discov· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R&D productivity: on the comeback trail.
Ulrik Schulze, Mathias Baedeker, Yen Ting Chen, David Greber

Nat Rev Drug Discov· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structures of two histidine ammonia-lyase modifications and implications for the catalytic mechanism.
Mathias Baedeker, Georg E Schulz

Eur J Biochem· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autocatalytic peptide cyclization during chain folding of histidine ammonia-lyase.
Mathias Baedeker, Georg E Schulz

Structure· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis